Abstract

 Evidence from 1 retrospective cohort study (identified in 1 systematic review) suggested that anakinra may reduce 28-day mortality and the risk for death in adults diagnosed with hemophagocytic lymphohistiocytosis (HLH).
 Due to the very low certainty of evidence from the single cohort study included in the systematic review, there is insufficient information to draw reliable conclusions regarding the clinical effectiveness of anakinra compared to standard treatments for patients diagnosed with HLH.
 No evidence on the safety or cost-effectiveness of anakinra compared to current standard treatments or to placebo was identified.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
